{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=20", "query": { "intervention": "capecitabine", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 760, "total_pages": 76, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T03:52:57.801Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00811993", "title": "A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "RG1507", "type": "DRUG" }, { "name": "RO1507", "type": "DRUG" }, { "name": "bevacizumab [Avastin]", "type": "DRUG" }, { "name": "capecitabine [Xeloda]", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "erlotinib [Tarceva]", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "pemetrexel", "type": "DRUG" }, { "name": "sorafenib", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "trastuzumab [Herceptin]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2009-02", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-27T03:52:57.801Z", "location_count": 8, "location_summary": "Tucson, Arizona • San Francisco, California • Santa Monica, California + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00811993" }, { "nct_id": "NCT00070252", "title": "Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Solid Neoplasm", "Inflammatory Breast Carcinoma", "Male Breast Carcinoma", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Tipifarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2003-09", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2015-05-04", "last_synced_at": "2026-10-27T03:52:57.801Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00070252" }, { "nct_id": "NCT00093808", "title": "Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "vinorelbine tartrate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2004-08", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2017-03-06", "last_synced_at": "2026-10-27T03:52:57.801Z", "location_count": 147, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 94 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Aurora", "state": "Illinois" }, { "city": "Bloomington", "state": "Illinois" }, { "city": "Canton", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00093808" }, { "nct_id": "NCT00093379", "title": "Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anal Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Radiation Therapy (XRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 20, "start_date": "2004-04", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2023-04-18", "last_synced_at": "2026-10-27T03:52:57.801Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00093379" }, { "nct_id": "NCT00478686", "title": "Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Phlebotomy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 102, "start_date": "2007-05-23", "completion_date": "2017-05-02", "has_results": false, "last_update_posted_date": "2017-05-08", "last_synced_at": "2026-10-27T03:52:57.801Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00478686" }, { "nct_id": "NCT00849550", "title": "Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific", "Cancer" ], "interventions": [ { "name": "capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Herbert Hurwitz", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2009-07", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2012-12-24", "last_synced_at": "2026-10-27T03:52:57.801Z", "location_count": 3, "location_summary": "Harvey, Illinois • Durham, North Carolina • Nashville, Tennessee", "locations": [ { "city": "Harvey", "state": "Illinois" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00849550" }, { "nct_id": "NCT00504660", "title": "6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Glioma of Brain", "Glioblastoma Multiforme", "Brain Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Celecoxib (Celebrex)", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "6-Thioguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 75, "start_date": "2003-09", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2012-01-11", "last_synced_at": "2026-10-27T03:52:57.801Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00504660" }, { "nct_id": "NCT02842125", "title": "Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Solid Tumor Cancer", "Recurrent Head and Neck Cancer" ], "interventions": [ { "name": "Ad-P53", "type": "DRUG" }, { "name": "Xeloda", "type": "DRUG" }, { "name": "Keytruda", "type": "DRUG" }, { "name": "Opdivo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MultiVir, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2018-11-20", "completion_date": "2020-05-08", "has_results": false, "last_update_posted_date": "2020-06-02", "last_synced_at": "2026-10-27T03:52:57.801Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02842125" }, { "nct_id": "NCT03770689", "title": "Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Rectal Cancer" ], "interventions": [ { "name": "Peposertib 50 mg", "type": "DRUG" }, { "name": "Peposertib 100 mg", "type": "DRUG" }, { "name": "Peposertib 150 mg", "type": "DRUG" }, { "name": "Peposertib 250 mg", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Radiotherapy (RT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2019-03-20", "completion_date": "2022-02-21", "has_results": true, "last_update_posted_date": "2023-03-21", "last_synced_at": "2026-10-27T03:52:57.801Z", "location_count": 10, "location_summary": "Aurora, Colorado • New Haven, Connecticut • Great Neck, New York + 7 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Great Neck", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03770689" }, { "nct_id": "NCT00570908", "title": "Brain Mets - Capecitabine Plus Sunitinib and WBRT", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "sunitinib", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "WBRT", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Baylor Breast Care Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 12, "start_date": "2009-02", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2014-09-18", "last_synced_at": "2026-10-27T03:52:57.801Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00570908" } ] }